Seltorexant

Seltorexant
Clinical data
Other names	MIN-202; JNJ-42847922; JNJ-922
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone;
CAS Number	1293281-49-8 ;
PubChem CID	67116280;
ChemSpider	34989176;
Chemical and physical data
Formula	C21H22FN7O
Molar mass	407.443 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3;
	InChI InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+; Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N;

Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX₂ receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).^[1]^[2]^[3] As of December 2015, it is in phase II clinical trials for both insomnia and MDD.^[2]^[4]^[5]

References

^ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
^ ^a ^b Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.
^ Cristoph Boss; Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012. {{cite journal}}: Cite journal requires |journal= (help)
^ "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.

External links

Template:Signaling peptide/protein receptor modulators

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Christopher2014-1] Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.

[Zisapel2014-2] Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.

[Boss2015-3] Cristoph Boss; Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012. {{cite journal}}: Cite journal requires |journal= (help)

[AdisInsight-4] "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.

[PhRMA2014-5] Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.

[1]

[2]

[3]

[4]

[5]

v t e Insomnia medications
GABA_A receptor positive modulators	Benzodiazepines: Brotizolam Cinolazepam Climazolam Clorazepate Doxefazepam Estazolam Etizolam Flunitrazepam Flurazepam Flutoprazepam Haloxazolam Loprazolam Lormetazepam Midazolam Nimetazepam Nitrazepam Quazepam Temazepam Triazolam Nonbenzodiazepines/Z-drugs: Eszopiclone Zaleplon Zolpidem Zopiclone Others: Alcohols (e.g., ethchlorvynol, amylene hydrate, ethanol) Barbiturates (e.g., amobarbital, pentobarbital, phenobarbital, secobarbital) Bromides (e.g., potassium bromide, sodium bromide) Carbamates (e.g., meprobamate) Chloral hydrate Clomethiazole Kava Neurosteroids (e.g., progesterone, zuranolone^†) Paraldehyde Piperidinediones (e.g., glutethimide) Quinazolinones (e.g., methaqualone) Sulfonmethane Valerian
Antihistamines (H₁ receptor inverse agonists)	Alimemazine Captodiame Dimenhydrinate Diphenhydramine Doxylamine Etodroxizine Hydroxyzine Meclizine Methapyrilene Pheniramine Phenyltoloxamine Pimethixene Promethazine Propiomazine Pyrilamine Tricyclic antidepressants (e.g., amitriptyline, doxepin, trimipramine) Tetracyclic antidepressants (e.g., mirtazapine) Triprolidine
Orexin receptor antagonists	Daridorexant Lemborexant Seltorexant^† Suvorexant
Melatonin receptor agonists	Melatonin Ramelteon Tasimelteon
Miscellaneous	Antipsychotics (e.g., quetiapine, olanzapine, risperidone, chlorpromazine) Ashwagandha Benzoctamine Cannabinoids (e.g., cannabis, dronabinol (THC), nabilone) Chamomile Fenadiazole Gabapentinoids (e.g., gabapentin, pregabalin, phenibut) Hops Lavender Menthyl isovalerate Niaprazine Opioids (e.g., hydrocodone, oxycodone, morphine) Passion flower Scopolamine Serotonin precursors (tryptophan, 5-HTPTooltip 5-hydroxytryptophan) Sodium oxybate (GHB) Sympatholytics (e.g., clonidine, guanfacine, prazosin) Theanine Trazodone Tricyclic antidepressants (e.g., amitriptyline, doxepin, trimipramine) Tetracyclic antidepressants (e.g., mirtazapine) Valnoctamide
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Seltorexant

See also

References

Further reading

External links